Bronchogen
Also known as: Ala-Glu-Asp-Leu
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
Dosage
Fixed dose: 100-200 mg oral daily for 10-30 day cycles
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure
Half-Life Calculator →Administration
Oral capsule or subcutaneous injection (cycled)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Respiratory Support
Khavinson tetrapeptide proposed to support bronchial epithelial function and mucociliary clearance.
Anti-Inflammatory
Russian research suggests reductions in airway inflammation markers in animal models.
Tissue-Specific Bioregulation
Proposed gene-expression effects on lung tissue via promoter binding (Khavinson framework).
Mechanism of Action
Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.
For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.
As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.
Regulatory Status
Not FDA approved. Registered in Russia as a peptide bioregulator and used in Russian gerontology and pulmonology practice. Available internationally through Khavinson-affiliated suppliers.
Risks & Safety
Common
generally well tolerated in Russian observational studies.
Serious
very limited Western clinical data; not a substitute for evidence-based treatment of asthma, COPD, or other chronic respiratory disease.
Rare
allergic reactions.
Compare Bronchogen With
Research Papers
5Published: April 1, 2017
AI Summary
At nanomolar doses Bronchogen (Ala-Glu-Asp-Leu) acted like a phytohormone in tobacco callus, boosting growth and altering expression of CLE, KNOX1, and GRF developmental gene families. The authors infer a conserved epigenetic signalling role for the peptide.
Published: February 1, 2017
AI Summary
In a rat NO2-induced COPD model, Bronchogen reduced neutrophilic inflammation and normalised pro-inflammatory cytokines in lung lavage fluid. It also restored bronchial epithelial structure and raised secretory IgA and surfactant protein B.
Published: September 1, 2015
AI Summary
One month of Bronchogen reversed COPD-typical airway remodelling in rats, eliminating goblet cell hyperplasia, squamous metaplasia, and emphysema while restoring ciliated cells. Local immunity (IgA) and inflammatory cytokine profiles also normalised.
Published: May 1, 2012
AI Summary
Bronchogen tissue-specifically restored CXCL12 and Hoxa3 differentiation markers in aging human bronchial epithelial cells. The effect was strongest in late-passage cultures, suggesting a geroprotective mechanism.
Published: November 1, 2011
AI Summary
Fluorescence-labelled Bronchogen entered HeLa cell nuclei and bound DNA preferentially at CNG and CTG motifs, sites linked to cytosine methylation. The sequence selectivity supports a direct epigenetic mode of action.
Frequently Asked Questions
What is Bronchogen?
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
What is Bronchogen used for?
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
What is the dosage for Bronchogen?
Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson pulse-dosing protocol.
What are the side effects of Bronchogen?
Common: generally well tolerated in Russian observational studies. Serious: very limited Western clinical data; not a substitute for evidence-based treatment of asthma, COPD, or other chronic respiratory disease. Rare: allergic reactions.
How does Bronchogen work?
Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes. For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers. As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.
How is Bronchogen administered?
Bronchogen is administered via oral capsule or subcutaneous injection (cycled).
What is the half-life of Bronchogen?
The half-life of Bronchogen is Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure.
Is Bronchogen legal?
Not FDA approved. Registered in Russia as a peptide bioregulator and used in Russian gerontology and pulmonology practice. Available internationally through Khavinson-affiliated suppliers.
Sources. This profile is built from peer-reviewed papers indexed on PubMed, FDA-approved labelling where available, and published clinical guidelines. The 5 primary sources used are listed in the Research Papers section above, each linked to its PubMed entry. See our editorial standards for how we research and review peptide profiles.
Last reviewed. by the Peptide Reference Editorial Team. Spot an error? Email a correction.
Not medical advice. Information on this page is for educational and research reference only. Many peptides covered are not approved for human use. See our full medical disclaimer.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
Ara-290
A peptide derived from EPO (the hormone that boosts red blood cells) but engineered to keep only the tissue-protective effects — it doesn't increase red blood cells at all. It activates the body's repair receptors to protect tissues and regenerate nerves. Particularly promising for nerve damage and tissue injury from poor blood flow. People use it for diabetic nerve damage and similar conditions.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
BPC-157 + TB-500
A two-in-one product that pairs BPC-157 and TB-500 to target different healing pathways. BPC-157 focuses on gut, tendon, and ligament repair by supporting blood vessel growth and nitric oxide signaling, while TB-500 helps cells move to injury sites for body-wide tissue repair. The most popular peptide combination for healing and recovery.